Liquidia Corporation Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Liquidia Corporation Common Stock trades at $34.05 (market cap $3.04B), while Vir Biotechnology Inc. Common Stock trades at $10.5 (market cap $1.76B). The key difference: Liquidia Corporation Common Stock is the larger of the two by market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| LQDA | VIR | |
|---|---|---|
Market Cap | $3.04B | $1.76B |
Volume | 21,111,778 | 2,764,948 |
Sector | Health | Health |
52-Week High | $91.03 | $11.78 |
52-Week Low | $22.02 | $5.12 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.94B | $1.32B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →